Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women

Obstetrics and Gynecology

Volumn 100, Issue 3, 2002, Pages 495-504

  Lemay, André ^a   Dodin, Sylvie ^a   Kadri, Nadine ^b   Jacques, Hélène ^a   Forest, Jean Claude ^b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; CONJUGATED ESTROGEN; FIBRINOGEN; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PHYTOESTROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; TRIACYLGLYCEROL;

ANTHROPOMETRY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE BINDING; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYSTERECTOMY; INSULIN BLOOD LEVEL; LINSEED; MENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERUS;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; ESTROGENS, CONJUGATED (USP); FEMALE; FLAX; HORMONE REPLACEMENT THERAPY; HUMANS; HYPERCHOLESTEROLEMIA; MENOPAUSE; MIDDLE AGED; PROBABILITY; PROGNOSIS; TREATMENT OUTCOME;

EID: 0036710986     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02123-3     Document Type: Article

References (35)

1. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., Delbanco T.L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 328:1993;246-252.
2. Eisenberg D.M., Davis R.B., Ettner S.L., Appel S., Wilkey S., Van Rompay M., et al. Trends in alternative medicine use in the United States, 1990-1997 Results of a follow-up national survey. JAMA. 280:1998;1569-1575.
3. Scambia G., Mango D., Signorile P.G., Anselmi Angeli R.A., Palena C., Gallo D., et al. Clinical effects of a standardized soy extract in postmenopausal women A pilot study. Menopause. 7:2000;105-111.
4. Upmalis D.H., Lobo R., Bradley L., Warren M., Cone F.L., Lamia C.A. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women A multicenter, double-blind, randomized, placebo-controlled study. Menopause. 7:2000;236-242.
5. The role of isoflavones in menopausal health Consensus opinion of The North American Menopause Society. Menopause. 7:2000;215-229.
6. Hodgson J.M., Puddey I.B., Beilin L.J., Mori T.A., Croft K.D. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations A randomized controlled trial in humans. J Nutr. 128:1998;728-732.
7. Baum J.A., Teng H., Erdman J.W., Weigel R.M., Klein B.P., Persky V.W., et al. Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr. 68:1998;545-551.
8. Simons L.A., von Konigsmark M., Simons J., Celermajer D.S. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol. 85:2000;1297-1301.
9. Cunnane S.C., Ganguli S., Menard C., Liede A.C., Hamadeh M.J., Chen Z.Y., et al. High alpha-linolenic acid flaxseed (Linum usitatissimum) Some nutritional properties in humans. Br J Nutr. 69:1993;443-453.
10. Bierenbaum M.L., Reichstein R., Watkins T.R. Reducing atherogenic risk in hyperlipemic humans with flax seed supplementation A preliminary report. J Am Coll Nutr. 12:1993;501-504.
11. Arjmandi B.H., Khan D.A., Juma S., Drum M.L., Venkatesh S., Sohn E., et al. Whole flaxseed consumption lowers serum LDL-cholesterol and lipoprotein(a) concentrations in postmenopausal women. Nutr Res. 18:1998;1203-1214.
12. Jenkins D.J., Kendall C.W., Vidgen E., Agarwal S., Rao A.V., Rosenberg R.S., et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity A controlled crossover trial. Am J Clin Nutr. 69:1999;395-402.
13. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
14. Vaisey-Genser M., Morris D. Flaxseed Health, nutrition and functionality. 1997;Flax Council of Canada, Winnipeg. Revised ed.
15. Kupperman H., Blatt M., Wiesdader H., Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab. 13:1953;688-703.
16. Canada, Health Services and Promotion Branch. Nutrient value of some common foods. 1988;National Health and Welfare, Ottawa.
17. Gionet N.J., Godin G. Self-reported exercise behavior of employees A validity study. J Occup Med. 31:1989;969-973.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
19. Armitage P., Hills M. The two-period crossover trial. The Statistician. 31:1982;119-131.
20. de Valk-de Roo G.W., Stehouwer C.D., Meijer P., Mijatovic V., Kluft C., Kenemans P., et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol. 19:1999;2993-3000.
21. Barrett-Connor E., Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 10:1990;531-534.
22. Godsland I.F., Gangar K., Walton C., Cust M.P., Whitehead M.I., Wynn V., et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism. 42:1993;846-853.
23. Boschetti C., Cortellaro M., Nencioni T., Bertolli V., Della Volpe A., Zanussi C. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thromb Res. 62:1991;1-8.
24. Koh K.K., Cardillo C., Bui M.N., Hathaway L., Csako G., Waclawiw M.A., et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 99:1999;354-360.
25. Gebara O.C., Mittleman M.A., Walsh B.W., Lipinska I., Welty F.K., Bellotti G., et al. Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia. Heart. 80:1998;235-239.
26. Davidson M.H., Maki K.C., Marx P., Maki A.C., Cyrowski M.S., Nanavati N., et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med. 160:2000;3315-3325.
27. Brzezinski A., Adlercreutz H., Shaoul R., Rösler A., Shmueli A., Tanos G., et al. Short-term effects of phytoestrogen-rich diet on postmenopausal women. Menopause. 4:1997;89-94.
28. Mashchak C.A., Lobo R.A., Dozono-Takano R., Eggena P., Nakamura R.M., Brenner P.F., et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 144:1982;511-518.
29. Chetkowski R.J., Meldrum D.R., Steingold K.A., Randle D., Lu J.K., Eggena P., et al. Biologic effects of transdermal estradiol. N Engl J Med. 314:1986;1615-1620.
30. De Lignieres B., Basdevant A., Thomas G., Thalabard J.C., Mercier-Bodard C., Conard J., et al. Biological effects of estradiol-17 beta in postmenopausal women Oral versus percutaneous administration. J Clin Endocrinol Metab. 62:1986;536-541.
31. Adlercreutz H., Mousavi Y., Clark J., Hockerstedt K., Hamalainen E., Wahala K., et al. Dietary phytoestrogens and cancer In vitro and in vivo studies. J Steroid Biochem Mol Biol. 41:1992;331-337.
32. Baird D.D., Umbach D.M., Lansdell L., Hughes C.L., Setchell K.D., Weinberg C.R., et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab. 80:1995;1685-1690.
33. Lindstedt G., Lundberg P.A., Lapidus L., Lundgren H., Bengtsson C., Bjorntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes. 40:1991;123-128.
34. Haffner S.M., Dunn J.F., Katz M.S. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. Metabolism. 41:1992;278-284.
35. Lipworth L., Adami H.O., Trichopoulos D., Carlstrom K., Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the etiology of postmenopausal breast cancer. Epidemiology. 7:1996;96-100.